Shares of Array BioPharma (ARRY -10.4%) are trading notably lower on the day.
The company says data presented today at ASH shows filanesib is active "in heavily pre-treated MM patients, with a consistent safety profile."
Results for heavily pre-treated patients (all of which were refractory to Velcade and 80% were refractory to Revlimid) receiving a filanesib/ Kyprolis combo treatment: 37% ORR and 63% CBR.
The Phase 1b dose escalation study also showed "filanesib and Kyprolis can be combined at the maximum planned dose for each agent."
Results for Phase 1b dose escalation study of a filanesib/Velcade combo in relapsed or refractory MM: 42% ORR for patients dosed at greater than or equal to 1.25 mg/m squared.
Results for Phase 2 study of single agent filanesib with dexamethasone in heavily pretreated MM: 16% ORR in "patients with a median of six prior therapies, previously treated with both Velcade and Revlimid." (PR)